137 related articles for article (PubMed ID: 3116443)
1. [Preventive treatment of rejection by the prolonged administration of OKT3: decrease of the immune response of the host].
Debure A; Chkoff N; Chatenoud L; Lacombe M; Campos H; Noël LH; Goldstein G; Bach JF; Kreis H
Nephrologie; 1987; 8(3):87-94. PubMed ID: 3116443
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
3. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
4. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
5. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
[TBL] [Abstract][Full Text] [Related]
6. Reexposure to OKT3 in renal allograft recipients.
Mayes JT; Thistlethwaite JR; Stuart JK; Buckingham MR; Stuart FP
Transplantation; 1988 Feb; 45(2):349-53. PubMed ID: 3278428
[TBL] [Abstract][Full Text] [Related]
7. Monitoring immunosuppression following renal transplantation.
Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
[TBL] [Abstract][Full Text] [Related]
8. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
Chatenoud L; Bach JF
Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
[TBL] [Abstract][Full Text] [Related]
9. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3.
Kemnitz J; Cremer J; Schaefers HJ; Restrepo-Specht I; Haverich A; Uysal A; Heublein B; Wirth S
J Heart Lung Transplant; 1991; 10(3):366-72. PubMed ID: 1906746
[TBL] [Abstract][Full Text] [Related]
10. Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.
De Pauw L; Abramowicz D; Goldman M; Vereerstraeten P; Kinnaert P; Toussaint C
Transplant Proc; 1990 Aug; 22(4):1759-60. PubMed ID: 2117800
[No Abstract] [Full Text] [Related]
11. Clinical development of Orthoclone OKT3.
Cosimi AB
Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
[No Abstract] [Full Text] [Related]
12. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
Monaco A; Goldstein G; Barnes L
Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
[No Abstract] [Full Text] [Related]
13. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
[TBL] [Abstract][Full Text] [Related]
14. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
15. OKT3 treatment of cardiac allograft rejection.
Haverty TP; Sanders M; Sheahan M
J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
Hanto DW; Jendrisak MD; McCullough CS; So SK; Marsh JW; Rush T; Michalski S; Phelan D; Mohanakumar T
Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
[No Abstract] [Full Text] [Related]
17. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
18. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients.
Debure A; Chkoff N; Chatenoud L; Lacombe M; Campos H; Noël LH; Goldstein G; Bach JF; Kreis H
Transplantation; 1988 Mar; 45(3):546-53. PubMed ID: 3279578
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B
J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
[TBL] [Abstract][Full Text] [Related]
20. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
McLigeyo SO; Notghi A; Anderton JL; Dick J
East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
